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Abstract
Based upon the lack of clinical samples available for research in many laboratories worldwide, a significant gap exists
between basic and clinical studies of beta-thalassemia major. To bridge this gap, we developed an artificially engineered
model for human beta thalassemia by knocking down beta-globin gene and protein expression in cultured CD34+ cells
obtained from healthy adults. Lentiviral-mediated transduction of beta-globin shRNA (beta-KD) caused imbalanced globin
chain production. Beta-globin mRNA was reduced by 90% compared to controls, while alpha-globin mRNA levels were
maintained. HPLC analyses revealed a 96% reduction in HbA with only a minor increase in HbF. During the terminal phases
of differentiation (culture days 14–21), beta-KD cells demonstrated increased levels of insoluble alpha-globin, as well as
activated caspase-3. The majority of the beta-KD cells underwent apoptosis around the polychromatophilic stage of
maturation. GDF15, a marker of ineffective erythropoiesis in humans with thalassemia, was significantly increased in the
culture supernatants from the beta-KD cells. Knockdown of beta-globin expression in cultured primary human erythroblasts
provides a robust ex vivo model for beta-thalassemia.
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therapeutic strategies. Efforts have been made to better understand the causes of ineffective erythropoiesis with clinical goals of
improving red cell production and reducing the burden of iron
overload. Our understanding of this cellular process remains
vague, in part, because bone marrow sampling is not regularly
performed. Major differences in the clinical phenotype also exist
between thalassemic patients with identical globin mutations. As
an alternative for in vivo studies, murine models of thalassemia
were developed, but differences between the murine models and
human beta-thalassemia major were reported [6–8]. In this study,
a synthetic model for human beta-thalassemia erythropoiesis is
reported as an experimental bridge between the non-human
models and the clinic. Lentiviral-mediated knockdown of betaglobin expression was studied using CD34+ cells obtained from
healthy human adults. This model reiterates several features of
ineffective erythropoiesis in human beta-thalassemia including
accumulation of insoluble alpha-globin protein and apoptosis at
the polychromatophilic stage of differentiation.

Introduction
Inherited mutations or deletions at the HBB gene locus on
chromosome 11p15.4 cause beta-thalassemia [1]. The heterozygous state is prevalent in tropical regions and likely plays a role in
protecting carrier populations from malarial disease [2]. There are
over 200 mutations or deletions that cause a beta-thalassemia
phenotype [3]. Homozygous or compound heterozygous inheritance causes more severe reductions in beta-globin gene and
protein expression. When hemoglobin production becomes
insufficient for the delivery of oxygen, regular and lifelong
erythrocyte transfusions are required.
Microcytic hypochromic anemia usually develops in betathalassemia during infancy or early childhood with the developmental loss of fetal hemoglobin expression. The pathophysiology
of this anemia is multifactorial and includes shortened survival of
erythrocytes in the peripheral blood. In addition, so-called
‘‘ineffective’’ erythropoiesis develops despite increased erythropoietin levels and packing of the marrow with erythroblasts. In
human beta-thalassemia, apoptotic cell death [4] is a major
mechanism by which there is a decrease in the number of
generated erythroblast precursor cells [5].
Studies of the molecular and cellular features of the betathalassemia phenotype are aimed toward novel diagnostic and
PLOS ONE | www.plosone.org

Materials and Methods
Ethics Statement
Approval for the research protocol and consent documents
pertaining to all studies using primary erythroblasts was granted by
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the Intramural National Institute of Diabetes and Digestive and
Kidney Diseases Institutional Review Board. Written informed
consent was obtained from all research subjects prior to
participation in this study.

Quantitative PCR Analyses for Gene Expression
On culture day 14, total RNA from three separate donors was
extracted using the RNeasy Plus kit (Qiagen, Valentia, CA) and
reverse transcribed using SuperScript III reverse transcriptase with
Oligo-dT(20) and RNase H treatment (Invitrogen). Real-time
PCR was performed on the ABI PRISM 7700 sequence detection
system instrument and software (Applied Biosystems, Foster City,
CA), using the manufacturer’s recommended conditions. QPCR
assays and PCR conditions were performed with primers, probes,
or Assays-on-Demand Gene Expression Products (Applied Biosystems) described previously [11]. Individual globin copy
numbers were calculated by comparison with standard curves
generated from a plasmid DNA encoding each globin template.

Cell Culture
Cryopreserved CD34+ cells obtained from healthy adult human
donors were used for all studies [9]. A 21 day ex vivo serum free
culture system was utilized that consists of two phases. In culture
phase I (culture days 1–7), CD34+ cells were placed in media
containing StemPro-34 complete media (l-glutamine, pen-strep
and StemPro-34 nutrient supplement) (Invitrogen, Carlsbad, CA)
supplemented with 50 ng/ml SCF (HumanZyme, Chicago, IL),
50 ng/ml FLT3-Ligand (HumanZyme) and 10 ng/ml IL-3
(HumanZyme). After 7 days, the cells were transferred to
erythropoietin (EPO; Amgen) supplemented medium (phase 2;
culture days 7–21) which is comprised of the following: StemPro34 complete medium, 4 U/ml EPO, 3 mM mifepristone (Sigma
Aldrich, St. Louis, MO), 10 mg/ml insulin (Sigma Aldrich), 3 U/
ml heparin (Hospira, Inc, Lake Forest, IL) and 0.8 mg/ml holo
transferrin (Sigma Aldrich). Purecell NEO Neonatal High
Efficiency Leukocyte Reduction Filter for Red Blood Cells (Pall
Life Sciences, Ann Arbor, MI) was used to purify enucleated red
blood cells on culture day 21.

HPLC Analysis of Fetal and Adult Hemoglobin
Cells (1.56106) were pelleted and resuspended in 120 ml of
distilled water followed by lysing through repeated freeze-thaw
cycles in a dry ice ethanol bath. Cell debris was removed by
centrifugation and filtration through Ultrafree-MC devices (Millipore, Billerica, MA). Samples (80 ml) were analyzed for HbF and
HbA using a 204 mm POLYCATA column (Poly LC, Columbia,
MD) fitted to a Gilson HPLC system (Gilson, Middleton, WI)
[9,12]. HPLC globin peaks were quantitated and compared using
Gilson Unipoint LC software (version 5.11). Total areas under the
HbA and HbF peaks were used for ratio comparisons.

Flow Cytometry Analysis
Immunostaining with antibodies directed against CD71 (Invitrogen) and glycophorin A (GPA) (Invitrogen) were performed to
assay cell differentiation on culture days 14, 18, and 21 using the
BD FACSAria I flow cytometer (BD Biosciences, San Jose, CA)
[10]. Positively stained populations of cells were defined by
fluorescence of more than two standard deviations above the
unstained cells. A minimum of 5000 live cell events was recorded.
Apoptosis was analyzed by flow cytometry using the Annexin V:
PE Apoptosis Detection Kit I (BD Biosciences) according to
manufacturer’s instructions. Intracellular staining was utilized for
the detection of the active form of caspase-3, where approximately
500,000 cells were fixed and permeabilized using the BD Cytofix/
Cytoperm Fixation/Permeabilization kit (BD Biosciences) and
stained with caspase-3 (BD Biosciences), according to the
manufacturer’s protocol. Apoptosis was induced in Jurkat cells
following treatment with camptothecin (Sigma Aldrich) for use as a
positive control.

Protein Isolation and Western Analyses
For protein isolation, three million cells were lysed with 250 ml
RIPA buffer in the presence of HALT protease inhibitor cocktails
(Pierce) according to the manufacturer’s instructions. After
centrifugation at 16,000 g for 10 minutes, the soluble and
insoluble fractions were collected, and the soluble protein
concentrations were measured using Coomassie Plus (Bradford)
Assay kit (Pierce). The insoluble fractions were washed with ice
cold 1X PBS twice, and solubilized by boiling in 35 ml 2X LDS
buffer (Invitrogen) [13].
Equal amounts of protein (20–30 mg) were separated by gel
electrophoresis using NuPAGE Novex 4–12% Bis-Tris gel in
MOPS buffer and transferred using the iBlot Blotting System with
nitrocellulose membranes (Invitrogen). Blots were probed with
antibodies against human alpha-globin (Santa Cruz Biotechnology, Santa Cruz, CA), beta-globin (Abnova, Walnut, CA), gammaglobin (Abnova), and the appropriate horseradish peroxidaseconjugated secondary antibodies (Santa Cruz Biotechnology).
Immunoreactive proteins were detected and visualized using ECL
Plus Western detection reagents (GE Healthcare, Pascataway, NJ).
Soluble fractions were probed for beta-actin (Abcam, Cambridge,
MA) antibody, and insoluble fractions were probed for glycophorin A (Santa Cruz biotechnology) as loading controls. Band
intensities were analyzed using the Image J software program
(http://rsbweb.nih.gov/ij/).

Lentiviral shRNA Transduction
Clone
TRCN0000232626
59-CCGGCTTGGACCCAGAGGTTCTTTGCTCGAGCAAAGAACCTCTGGGTCCAAGTTTTTG-39 (Sigma Aldrich) targeting human beta-globin
mRNA was used. Non-targeting shRNA control SHC002V
(Sigma Aldrich) served as donor-matched controls. Cryopreserved
CD34+ cells were washed and placed in phase I culture medium at
an initial concentration of 250,000 cells/ml. After three days,
300,000 cells were transduced in 300 ml of phase I culture medium
containing the viral particles (multiplicity of infection of 12). After
24 hours, the cells were resuspended in 4.0 ml phase I culture
medium containing 0.5 mg/ml puromycin for an additional three
days prior to pelleting and resuspension in 15 ml of phase II
culture medium. The phase II culture medium was not
supplemented with puromycin, since puromycin selection of
mock-transduced cells resulted in complete cell death under these
conditions.

PLOS ONE | www.plosone.org

ELISA Analysis
Quantification of GDF15 was performed on serum from culture
day 21 cells using the DuoSet ELISA for human GDF15 (R&D
Systems) following the manufacturer’s protocol [14]. The optical
density was read utilizing the ELx808 Absorbance Microplate
Reader (BioTek, Winooski, VT).

Statistical Analysis
Replicate data are expressed as means 6 standard deviation
(SD) with significance calculated by Student’s t test.
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Results

Analysis of Hemoglobin and Cellular Phenotype upon
Completion of Cultured Differentiation

Globin mRNA Expression Pattern

HPLC was performed from 1.56106 cells collected from control
and beta-KD cells on culture day 21 for measurement of adult
(HbA) and fetal hemoglobin (HbF). Representative HPLC tracings
are shown from control and beta-KD cells in Figure 2A and B,
respectively. As expected, the control cells contained relatively low
HbF (2.960.7%) levels, but the percentage significantly increased
to 49.369.3% in the beta-KD cells. Since the increase in the HbF
percentage was not reflected in the gamma-globin mRNA, total
area under the HbA and HbF peaks were measured in Figure 2C–
D. Consistent with the beta-KD reduction in .90% of beta-globin
mRNA, the total area measured under the HbA peak was also
reduced 11.8 fold (p,0.01), and the total area measured under the
HbF peak remained relatively unchanged with a slight increase
that did not reach statistical significance. Therefore, the increased
percentage of HbF shown in Figure 2A–B reflects a significant
decrease in the HbA production in the beta-KD cells.
Wright-Giemsa staining of culture day 21 cytospins from
control (Figure 2E) showed a main population of orthrochromatic
normoblasts. In contrast, the beta-KD cells (Figure 2F) demonstrated a less mature phenotype (polychromatophilic normoblasts).
Many abnormal orthrochromatic normoblasts were seen with
reduced cytoplasmic volume and decreased hemoglobinization
compared to the matched controls. The cellular morphology
suggested major erythroid defects around the polychromatophilicorthochromatic stage of differentiation similar to that identified in
human beta-thalassemia marrow [5]. In addition to nucleated
cells, the two-phase serum free culture model permitted differentiation into enucleated erythrocytes. Mature erythrocytes were
examined after filtering the culture day 21 cells through a
leukocyte reduction filter from control and beta-KD cells followed
by Wright-Giemsa staining. Figure 2G shows the formation of
mature erythrocytes in the control cultures (day 21). In the betaKD cultures, rare enucleated cells with pale blue cytoplasm were
identified as well as occasional hemoglobinized cells (Figure 2H).

Human CD34+ cells from healthy volunteers were cultured ex
vivo for 21 days in a two-phase, serum free system to engineer a
beta-thalassemia major model. shRNA technology was employed
to target silencing of human beta-globin mRNA expression.
Informatics analyses of the TRCN0000232626 clone sequence
revealed reduced levels of both beta- and delta-globin mRNA.
Globin mRNA expression profiles were measured in three
separate donors on culture day 14 by QPCR as previously
described [11]. Figure 1A shows that greater than 90% of betaglobin mRNA was silenced when compared to the control (nontargeting shRNA, SHC002V) (control = 4.0610761.46106 copies/ng cDNA vs. beta-KD = 2.5610661.66106 copies/ng cDNA,
p = 0.01). The gamma-globin mRNA demonstrated a less than 2
fold increase in beta-KD when compared to control (control = 1.7610661.26106
copies/ng
cDNA
vs.
betaKD = 3.4610661.46106 copies/ng cDNA). Delta-globin mRNA
showed a 4.5 fold decrease in beta-KD compared to the control
(control = 6.9610568.36104 copies/ng cDNA vs. betaKD = 1.5610562.36104 copies/ng cDNA). There was an insignificant increase in the expression of epsilon-globin mRNA.
Alpha-globin locus mRNA expression (alpha-, mu-, theta-, zeta-,
globin) shown in Figure 1B demonstrated no significant changes in
mRNA levels compared to controls.

Effects of Beta-KD Knockdown on the Erythroblast
Growth and Differentiation
Cell counts performed on culture days 14 and 21 from three
independent donors demonstrated a significant reduction in
proliferation during the second phase of culture. Average cell
counts of beta-KD on culture day 14 showed a significant 3.3 fold
reduction compared to control (control = 3.4610567.96104 cells/
ml vs. beta-KD = 1.0610561.96104 cells/ml). On culture day 21,
the average cell counts were further increased in control cell
cultures, but remained unchanged in the beta-KD cells (concells/ml
vs.
betatrol = 5.6610568.16104
KD = 1.1610562.66104 cells/ml).
Cell maturation was defined by expression of erythroid markers
CD71 and GPA as previously described [9]. Representative data
are shown in Figure 3 with descriptive statistics from triplicate
experiments provided in Table S1. The main population on
culture day 14 consisted of CD71 high/GPA(+) cells (proerythroblast stage of differentiation) in both control and beta-KD,
respectively. As the cells undergo the final stages of differentiation,
there is a subsequent loss of CD71. In the beta-KD cells, a
significantly lower percent of GPA(+)/CD71(-) cells was detected
compared to control in culture day 18 cells (representative data
shown in Figures 3C, 3D; triplicate experiments: GPA(+)/CD71(-);
control = 28.165.8% vs. beta-KD = 1.660.5%, p = 0.02). On
culture day 21, the cellular phenotypes were similar to those on
culture day 18 suggesting the absence of further differentiation

Figure 1. QPCR Quantitation of globin mRNA. RNA samples from
erythroblasts cultured on day 14 were examined for globin mRNA
expression using quantitative PCR. (A) Expression levels of beta-,
gamma-, delta-, and epsilon-globins. (B) Expression levels of alpha-, mu, theta-, and zeta-globins. Average copy number per ng cDNA is shown
on the y-axis from three separate donors, control (black bar) and betaKD (open bar). Standard deviation bars are shown in vertical lines.
Asterisks signify statistical significance of p,0.05.
doi:10.1371/journal.pone.0068307.g001

PLOS ONE | www.plosone.org
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Figure 3. Flow cytometry analysis of terminal differentiation.
Representative dot plots from (A) culture day 14 control erythroblasts,
(B) culture day 14 beta-KD erythroblasts, (C) culture day 18 control
erythroblasts, (D) culture day 18 beta-KD erythroblasts, (E) culture day
21 control erythroblasts, and (F) culture day 21 beta-KD erythroblasts.
Cells were double stained with glycophorin A (GPA) and transferrin
receptor (CD71).
doi:10.1371/journal.pone.0068307.g003

Western Analysis of Soluble and Membrane Insoluble
Globin Fractions
Western analyses were performed to demonstrate the effects of
beta-globin chain imbalance upon alpha-, beta- and gammaglobin protein expression during terminal differentiation. Representative results are shown in Figure 4A of three separate donors.
These results are consistent with reduced beta-globin gene
expression, and beta-globin protein was also significantly reduced.
Statisitcal analyses of Western blot band intensities from three
independent donors were compared for all globins and normalized
to the loading control (beta-actin) on culture days 14, 18 and 21
(Table S2). The levels of cytosolic alpha-globin were significantly
lower in the beta-KD cells; however, the level of reduction was less
robust than that of beta-globin. Although gamma-globin was
increased in the beta-KD samples, the increases did not reach
statistical significance (Table S2).
Since human alpha-globin chains do not assemble into soluble
hemoglobin species, the globin chain imbalance caused by betathalassemia results in an excess of free alpha-globin chains. The
excess alpha-globin chains lose their solubility and precipitate in
the insoluble membrane fraction of erythrocytes and erythroblast
precursor cells as a hallmark of the disease [15]. Those precipitates
cause oxidative damage and contribute to the cellular demise. To
investigate whether the decreases in soluble alpha- globin chains

Figure 2. Hemoglobin and globin chain analyses. High performance liquid chromatography analyses of adult hemoglobin (HbA) and
fetal hemoglobin (HbF) from culture day 21 erythroblasts (A) Control,
(B) beta-KD. Total area under the (C) adult hemoglobin (HbA), and (D)
fetal hemoglobin (HbF) peaks was measured using 1.56106 cultured
cells from three donors. Each panel shows average values with standard
deviation bars from control (black bar) and beta-KD (open bar).
Cytospin preparations of the live cells were stained with Wright-Giemsa
on culture day 21 for (E) control cells, (F) beta-KD cells and (G)
enucleated control cells, (H) enucleated beta-KD cells with 10mm scale
bars. Asterisks signify statistical significance of p,0.05.
doi:10.1371/journal.pone.0068307.g002

(representative data shown in Figures 3E, 3F; triplicate experiments: GPA(+)/CD71(-); control = 17.666.3% vs. betaKD = 3.662.5%, p = 0.03). These results suggest globin chain
imbalances affect both the proliferative potential and differentiation of the beta-KD cells.

PLOS ONE | www.plosone.org
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control = 0.760.3%, p = 0.02) suggesting that apoptosis is initiated
relatively early during erythroblast maturation (Figure 5A). There
was an additional increase in active caspase-3 from culture day 14
to 18 in beta-KD erythroblasts. Conversely, Annexin V staining
was slightly increased, but did not achieve statistical significance
on culture day 14. However, by culture day 18, when orthochromatic normoblasts are the prevalent population in control cultures,
Annexin staining indicated that the majority of the population was
comprised of apoptotic cells in beta-KD (beta-KD = 75.863.3%,
vs. control = 35.9612.7%, p = 0.02) (Figure 5B). As such, the data
demonstrate early signs of apoptosis on culture day 14 followed by
a significant increase later in the culture period, which coincides
with the accumulation of insoluble alpha-globin in the cells.
GDF15, a marker of erythroblast apoptosis that is usually
increased in the serum of patients with thalassemia, was also
increased in the culture supernatants of the beta-KD cells
(Figure 5C). Increased apoptosis during the later stages of betaKD differentiation, as well as a significant increase in GDF15
expression represent characteristic features of ineffective erythropoiesis identified in human beta-thalassemia [5,14].

Discussion
Here we report an artificially engineered model of thalassemia
for ex vivo studies of human erythropoiesis developed using a
shRNA lentiviral vector to reduce beta-globin expression in
primary human erythroblasts. With this approach, terminal
differentiation from proerythroblasts to orthochromatic normoblasts and enucleated cells occurs from culture days 14–18
(Figure 3). Cultures were maintained for an additional three days
(days 18–21) to explore the potential for further differentiation of
the beta-KD cells. Overall, the strategy of knocking down betaglobin mRNA and protein expression resulted in phenotypic
changes consistent with those predicted for severe beta-thalassemia
in humans. The efficiency of the tested shRNA clone produced a
greater than 90% reduction in the levels of cellular beta-globin
mRNA when compared to control cells. Since the shRNA clone
(TRCN0000232626) also targets delta-globin mRNA [20], deltaglobin mRNA levels were reduced as shown by QPCR (Figure 1A).
However, gamma-globin levels increased slightly as determined by
QPCR (Figure 1A) and Western analyses (Figure 4A). By
comparison, alpha-globin mRNA remained stable. Major reductions in adult hemoglobin (HbA) and beta-globin chains were also
detected at the protein level. By the end of the culture period, fetal
hemoglobin (HbF) was the dominant hemoglobin variant in betaKD cells mainly because of the massive reduction in HbA. The
increase in HbF among the mature beta-KD cells may have also
caused improved survival of some cells during differentiation [21].
The terminal stages of differentiation in beta-KD cells were
marked by apoptosis of most cells, and only a thin ring of
hemoglobinized cytoplasm in many of the remaining orthochromatic normoblasts. The high levels of detected apoptosis reflect the
magnitude of beta-globin reduction, as well as the absence of
macrophage clearance of the apoptotic cells by phagocytosis.
Balanced globin chain synthesis coupled with heme biosynthesis
is required to produce sufficient quantities of hemoglobin for
effective erythropoiesis [22]. In beta-thalassemia major, the severe
chain imbalance of excess alpha-globin chains leads to the
formation of hemichromes (alpha-globin/heme aggregates), which
cause precipitates in the erythrocyte membrane [15]. Those
precipitates produce ROS damage and cell death. In beta-KD
cultures, soluble alpha-globin protein was reduced during the final
stages of maturation in association with deposition of insoluble
alpha-globin in the membranes. The cause for the smeared pattern

Figure 4. Soluble and insoluble globin analyses. (A) Western blot
analyses of globin chains were performed using total soluble cytosolic
protein (20 mg/lane) from day 14, 18, and 21 cultured erythroblasts.
Antibodies against alpha-globin, beta-globin, and gamma-globin were
used for comparison. Beta-actin was used as a loading control. (B)
Western analysis of the alpha-globin insoluble membrane fraction on
culture days 14, 18, and 21 of control and beta-KD cultured
erythroblasts. Fractions from equivalent cell number preparations were
used in each lane. GPA was used as a loading control for the insoluble
membrane proteins. Equivalent film exposure time (one minute) was
used for alpha-globin, beta-globin, and gamma-globin membrane
comparisons.
doi:10.1371/journal.pone.0068307.g004

on culture days 14, 18 and 21 were accompanied by increased
insoluble alpha-globin in the beta-KD cells, we studied the
insoluble membrane fractions [13] from culture day 14, 18 and 21
erythroblasts (Figure 4B). On culture day 14, alpha-globin was
barely detectable in the insoluble beta-KD extracts. In extracts
from more mature erythroblasts on culture day 18, major
accumulation of insoluble alpha-globin was detected compared
with the controls. A smeared pattern of alpha-globin protein at
higher molecular weights was seen. No further increase in
insoluble alpha-globin occurred after culture day 18.

Assessment of Apoptosis in Beta-KD Cells using Flow
Cytometry
Insoluble alpha-globin precipitation causes oxidative damage
and apoptosis of erythroblasts in humans with beta-thalassemia
[16,17]. Assessment of caspase-3 [18] and Annexin V [19]
expression were explored to determine if beta-KD similarly
caused apoptosis ex vivo. On culture day 14, there was a small
but significant increase in active caspase-3 that was detected in the
beta-KD cells compared to controls (beta-KD = 4.061.0% vs.
PLOS ONE | www.plosone.org
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mental design did not include mixed cell cultures, so potential roles
for macrophages in the production or clearance of viable or
apoptotic erythrocytes were not explored. Since the beta-KD
model reflects erythroblast differentiation in the absence of
additional cell membrane alterations that occur in vivo, microcytosis was not evident [23,24]. Among the enucleated cells,
hypochromia was obvious as several cells demonstrated an
erythroid ghost-like appearance. However, the low number of
enucleated beta-KD cells prevented more formal analyses of those
cells. Enucleated cells were reportedly absent from ex vivo cultures
of erythroblasts obtained from blood of thalassemia patients [25].
While we were unable to obtain the appropriate clinical samples
for direct comparisons to be made between ex vivo cultures of betaKD versus thalassemia-major erythroblasts as part of this study,
such comparisons should be made in laboratories where those cells
are available.
As demonstrated from other areas of biomedical research [26],
there exists an urgent need for disease models using primary
human cells or tissues. Considerable resources have been utilized
in recent decades to develop and explore murine models of
hemoglobinopathies. Despite their robustness for understanding
murine erythropoiesis in vivo, those disease models have not yet led
to successful clinical trials for improving the health for patients
with thalassemia. Differences between the kinetics of murine and
human erythroblast differentiation [27], iron biology [7,28–30],
and globin gene regulation [31] confound our ability to interpret
the murine data in the context of clinical application. As a result, a
considerable gap is developing between basic and clinical research
for beta-thalassemia.
This study was undertaken to characterize the effects of betaglobin chain imbalances upon ex vivo erythroblast differentiation
and survival using primary human cells. Our model for
knockdown of beta-globin gene expression may also permit
examinations of dysfunctional erythroblast heme metabolism or
mitochondrial function caused by globin chain imbalance [32].
Investigations of erythroblast GDF15 regulation [14] or caspase
related GATA-1 expression [33] can be explored further. Based
upon its simplicity and reproducibility, the model is being
developed for preclinical assessment and comparison with beta
thalassemia-related discoveries made in other model systems
including biochemical assays, immortalized cell lines, or genetically modified rodents [22]. Since the shRNA in this study does
not target gamma-globin mRNA, it should be possible to screen
and study fetal hemoglobin augmenting drugs or small molecules
for their potential to correct the beta-thalassemia phenotype.

Figure 5. Analysis for markers of apoptosis. Erythroblasts
collected on culture day 14, 18 and 21 were assessed for (A) early
apoptosis marker active caspase-3 and (B) late apoptosis marker
Annexin V. (C) GDF15 protein level in culture day 21 supernatants. Each
panel shows average values from three separate donors, control (black
bar) and beta-KD (open bar). Standard deviation bars are shown, and
asterisks signify statistical significance of p,0.05.
doi:10.1371/journal.pone.0068307.g005

Supporting Information
Table S1

(DOCX)
Table S2

(DOCX)

of insoluble alpha hemoglobin seen in the Western analyses is
unknown, but may be related to the absence of macrophage
clearance of the apoptotic cells or ubiquitination of the free alphaglobin chains [13]. The accumulation of free alpha-globin in the
membranes coincided with apoptosis of the beta-KD cells during
the period of maturation when hemoglobin accumulates in donormatched control cells.
Despite several similarities between the ex vivo beta-KD model
and clinical defects in erythropoiesis reported in vivo for betathalassemia, it must be emphasized that the findings do not
completely reflect the beta-thalassemia phenotype. The experi-
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